Mylan Triumphs In Tecfidera Patent Challenge
Biogen's Tecfidera Future Uncertain After Patent Challenge Loss To Mylan
Following a district court decision invalidating the '514 patent for Tecfidera, Mylan says it looks forward to launching a generic after final FDA approval is granted, despite Biogen saying it will appeal the ruling. The ANDA has a November action date.
